Medtronic’s Drug-Coated Balloon Impresses In Peripheral Artery Trial
This article was originally published in The Gray Sheet
Executive Summary
Medtronic may have gained an edge over C.R. Bard in the future U.S. drug-coated balloon market as one-year results of a randomized trial of its IN.PACT Admiral paclitaxel-coated peripheral angioplasty balloon appear to be the best yet for a peripheral intervention device.
You may also be interested in...
Medtronic, Bard In Close Race To First FDA-Approved Drug-Eluting Balloon
Medtronic says it reached the necessary trial enrollment to support PMA approval for its IN.PACT Admiral drug-eluting balloon catheter to treat atherosclerosis in the superficial femoral artery. On the same day, CR Bard said it was prepared to submit its final PMA module for its Lutonix drug-eluting balloon by year’s end.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.